NCT05991323

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

A Prospective Observational Study of Patients Receiving Dupilumab for Prurigo Nodularis

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Detailed description

The follow-up period will be 18 months or until death, loss to follow-up, or withdrawal, whichever comes first.

Conditions

• Prurigo Nodularis

Interventions

Type	Name	Description
DRUG	Dupilumab	Injection solution; subcutaneous

Timeline

• Start date: 2023-12-12
• Primary completion: 2026-09-22
• Completion: 2026-09-22
• First posted: 2023-08-14
• Last updated: 2025-09-16

Locations

49 sites across 6 countries: United States, Canada, China, France, Japan, Netherlands